as of —
₹—
Change
—
Day Open
₹—
Day High
₹—
Day Low
₹—
NSE Close — 19 Nov 2026
₹148.82
Change
+13.35 (9.85%)
Open
₹134.0
Prev. Close
₹135.47
Day High
₹159.46
Day Low
₹133.81
Volume Analysis
Traded
1,549,508
Delivered
204,753
Delivery %
13.21%
End-of-day NSE price via the official Bhavcopy — updated once daily after market close, not a live tick.
Strengths, Weaknesses, Opportunities & Threats
Strengths (0)
No signal for this stock
Weaknesses (3)
- •Low return on equity (1.59%)
- •Promoter holding is falling
- •Below-average fundamentals quality score (45/100)
Opportunities (0)
No signal for this stock
Threats (0)
No signal for this stock
Rule-based signals from the fundamentals below — not investment advice.
Pivot Levels
| Type | R3 | R2 | R1 | Pivot | S1 | S2 | S3 |
|---|---|---|---|---|---|---|---|
| Classic | ₹186.56 | ₹173.01 | ₹160.91 | ₹147.36 | ₹135.26 | ₹121.71 | ₹109.61 |
| Fibonacci | ₹173.01 | ₹163.21 | ₹157.16 | ₹147.36 | ₹137.56 | ₹131.51 | ₹121.71 |
| Camarilla | ₹155.87 | ₹153.52 | ₹151.17 | ₹147.36 | ₹146.47 | ₹144.12 | ₹141.77 |
Support/resistance levels for today, calculated from the previous trading day's high/low/close.
Absolute Returns
YTD
+111.48%
1 Week
+5.53%
1 Month
+12.5%
3 Months
+19.03%
6 Months
+48.58%
1 Year
+102.72%
2Y/3Y/5Y not shown yet — price history tracking only goes back to mid-2025 so far.
Stock Vitals
Computed from the latest available annual financials.
Graham Number
₹36.56
Current price is above the Graham Number — Benjamin Graham's estimate of fair value based on earnings and book value.
DuPont ROE Breakdown
0.61%
Net margin 0.48% × asset turnover 0.68x × equity multiplier 1.87x
Company Overview
Sector
Healthcare
Market Cap
₹756 Cr
P/E (TTM)
365.0
ROE
1.59%
Book Value
₹54.5
Face Value
₹10.0
Source: Screener.in (Consolidated figures) — data as of 16 Nov 2026. Not investment advice.
TopFund Analysis
Zim Laboratories Limited scores weakly on TopFund's composite fundamentals check within the Healthcare sector, at 45/100. The strongest factor is Financial Strength (88/100), while Growth (5/100) is the weakest area to weigh before deciding. Notably: Low return on equity (1.59%); promoter holding is falling.
TopFund Score — Fundamentals Quality
45/100 — WeakData confidence: 80/100 (High Confidence) — based on how complete and how fresh the underlying data is.
As of 19 Nov 2026 · How we calculate this →
Financial Strength
Growth
Valuation
Cash Flow
Corporate Governance
Momentum
Institutional Ownership
Business Quality
Risk & Volatility
Liquidity
From Screener.in
- +Company's working capital requirements have reduced from 52.8 days to 41.0 days
- −Stock is trading at 2.59 times its book value
- −Though the company is reporting repeated profits, it is not paying out dividend
- −Company has low interest coverage ratio.
- −The company has delivered a poor sales growth of 4.03% over past five years.
Not investment advice — an automated read of public fundamentals data, for research context only.
Corporate Actions
Transcript of Q2 & H1FY27 Earnings Conference Call
Audio recording of Q2 and H1 FY27 earnings conference call available on company website.
The Newspaper Publication of financial results for the Quarter & Half yearly ended 30th September, 2026.
Zim Labs released Q2&H1 FY27 presentation: revenue ₹1,054 Mn, EBITDA ₹77 Mn, TGA GMP approval, CAPA progress.
Source: BSE regulatory filings, via Screener.in.
Quarterly Results
Last several quarters
| Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 86 | 96 | 118 | 82 | 92 | 96 | 109 | 72 | 89 | 109 | 105 | 94 | 105 |
| Expenses + | 77 | 85 | 102 | 74 | 83 | 85 | 94 | 68 | 83 | 96 | 98 | 92 | 100 |
| Operating Profit | 9 | 12 | 16 | 8 | 10 | 12 | 15 | 4 | 6 | 13 | 7 | 2 | 5 |
| OPM % | 10.87% | 11.98% | 13.28% | 9.83% | 10.34% | 12.0% | 13.43% | 5.92% | 6.49% | 11.79% | 6.83% | 2.6% | 5.15% |
| Other Income + | 1 | 1 | 2 | 1 | 1 | 2 | 2 | 1 | 2 | 2 | 6 | 1 | 2 |
| Interest | 1 | 2 | 2 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 4 | 4 |
| Depreciation | 4 | 4 | 4 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 7 |
| Profit before tax | 5 | 7 | 11 | 1 | 3 | 6 | 8 | -2 | 0 | 6 | 5 | -6 | -3 |
| Tax % | 23.71% | 31.81% | 26.48% | 27.42% | 19.59% | 30.0% | 39.7% | -22.63% | 23.53% | 27.27% | 24.29% | -28.01% | -25.18% |
| Net Profit + | 4 | 5 | 8 | 1 | 2 | 4 | 5 | -2 | 0 | 4 | 4 | -4 | -2 |
| EPS in Rs | 1 | 1 | 2 | 0 | 0 | 1 | 1 | 0 | 0 | 1 | 1 | -1 | 0 |
| Raw PDF | — | — | — | — | — | — | — | — | — | — | — | — | — |
| YoY Sales growth | -14 | -5 | 12 | 21 | 7 | 0 | -8 | -12 | -4 | 13 | -3 | 31 | 19 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Profit & Loss (Yearly)
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 266 | 269 | 235 | 273 | 335 | 278 | 307 | 333 | 399 | 367 | 379 | 374 | 414 |
| Expenses + | 278 | 239 | 203 | 238 | 293 | 255 | 268 | 292 | 347 | 326 | 335 | 344 | 386 |
| Operating Profit | -12 | 30 | 32 | 35 | 42 | 23 | 40 | 41 | 52 | 41 | 44 | 30 | 28 |
| OPM % | -4.4% | 11.0% | 13.0% | 13.0% | 13.0% | 8.0% | 13.0% | 12.0% | 13.0% | 11.0% | 12.0% | 8.0% | 7.0% |
| Other Income + | 2 | -2 | 5 | 9 | 2 | 5 | -3 | 4 | 6 | 5 | 6 | 11 | 11 |
| Interest | 10 | 14 | 10 | 9 | 11 | 13 | 11 | 8 | 6 | 7 | 11 | 13 | 14 |
| Depreciation | 7 | 9 | 9 | 10 | 11 | 14 | 16 | 16 | 17 | 16 | 20 | 20 | 22 |
| Profit before tax | -27 | 5 | 18 | 25 | 22 | 0 | 10 | 21 | 35 | 24 | 18 | 8 | 3 |
| Tax % | -19.0% | 5.0% | -6.0% | 23.0% | 30.0% | -4,600.0% | 28.0% | 31.0% | 31.0% | 27.0% | 32.0% | 29.0% | — |
| Net Profit + | -22 | 5 | 19 | 19 | 15 | 3 | 7 | 15 | 24 | 17 | 12 | 6 | 2 |
| EPS in Rs | — | — | — | — | 3 | 1 | 2 | 3 | 5 | 4 | 3 | 1 | 0 |
| Dividend Payout % | 0.0% | 16.0% | 4.0% | 4.0% | 5.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — |
| Sales growth | — | 1 | -12 | 16 | 23 | -17 | 11 | 9 | 20 | -8 | 3 | -1 | 13 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Balance Sheet
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | Sep 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reserves | 86 | 91 | 110 | 129 | 135 | 138 | 145 | 159 | 152 | 190 | 204 | 243 | 239 |
| Borrowings + | 93 | 96 | 81 | 81 | 77 | 90 | 82 | 53 | 62 | 112 | 118 | 127 | 148 |
| Other Liabilities + | 78 | 61 | 60 | 81 | 100 | 82 | 82 | 112 | 79 | 96 | 102 | 116 | 107 |
| Total Liabilities | 265 | 256 | 259 | 298 | 328 | 325 | 325 | 342 | 342 | 447 | 472 | 539 | 548 |
| Fixed Assets + | 87 | 92 | 89 | 94 | 106 | 116 | 107 | 106 | 109 | 161 | 164 | 162 | 227 |
| CWIP | 6 | 3 | 4 | 8 | 13 | 10 | 11 | 12 | 27 | 42 | 70 | 96 | 55 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Assets + | 172 | 161 | 166 | 196 | 209 | 200 | 208 | 224 | 206 | 244 | 237 | 282 | 267 |
| Total Assets | 265 | 256 | 259 | 298 | 328 | 325 | 325 | 342 | 342 | 447 | 472 | 539 | 548 |
| Equity Capital | 8 | 8 | 8 | 8 | 16 | 16 | 16 | 16 | 49 | 49 | 49 | 54 | 54 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Cash Flow
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operating Activity + | — | 22 | 32 | 37 | 35 | 22 | 32 | 49 | 38 | 16 | 41 | 50 |
| Cash from Investing Activity + | — | -12 | -7 | -26 | -21 | -18 | -6 | -14 | -35 | -73 | -40 | -55 |
| Cash from Financing Activity + | — | -10 | -25 | -10 | -15 | -3 | -26 | -33 | 1 | 60 | -9 | 28 |
| Net Cash Flow | — | 0 | 0 | 1 | -1 | 1 | 0 | 2 | 3 | 3 | -8 | 23 |
| Free Cash Flow | — | 9 | 24 | 8 | 15 | 3 | 25 | 34 | 1 | -57 | 1 | 11 |
| CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit | — | 77 | 109 | 117 | 85 | 119 | 83 | 121 | 86 | 46 | 92 | 177 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Shareholding Pattern
Quarter-by-quarter — Promoters, FII, DII & public holding trend
| Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Public | 66.74% | 66.74% | 66.74% | 66.73% | 66.29% | 66.49% | 66.46% | 66.52% | 66.52% | 69.57% | 68.28% | 68.35% |
| Promoters | 33.26% | 33.26% | 33.26% | 33.26% | 33.26% | 33.26% | 33.26% | 33.26% | 33.26% | 30.35% | 30.36% | 30.3% |
| FII | 0.0% | 0.01% | 0.0% | 0.0% | 0.21% | 0.01% | 0.03% | 0.0% | 0.02% | 0.0% | 0.03% | 0.17% |
| DII | 0.0% | 0.0% | 0.0% | 0.0% | 0.24% | 0.24% | 0.24% | 0.24% | 0.2% | 0.07% | 1.34% | 1.19% |
Source: Screener.in — quarterly shareholding disclosures.
Peers Comparison
Healthcare — ranked by market cap
| Company | Market Cap (Cr) | P/E | P/B | ROE |
|---|---|---|---|---|
| Zim Laboratories Limited (this stock) | 756 | 365.0 | 2.59 | 1.59% |
| Gaudium Ivf N Women H L | 740 | 32.0 | 4.55 | 24.6% |
| Shree Ganesh Remedies Ltd | 798 | 65.9 | 4.79 | 10.8% |
| Kilitch Drugs India Ltd | 805 | 33.4 | 2.79 | 10.6% |
| Wanbury Limited | 676 | 20.3 | 4.3 | 76.5% |
| Health X Platform Limited | 862 | 510.0 | 1.36 | 0.44% |
| Rays Of Belief Limited | 615 | 99.3 | 4.03 | 16.1% |
Which Mutual Funds Hold Zim Laboratories Limited?
Frequently Asked Questions about Zim Laboratories Limited
Zim Laboratories Limited (ZIMLAB) closed at ₹148.82 on NSE on 19 November 2026, up 13.35 (9.85%) from the previous close.
Zim Laboratories Limited trades on the NSE (National Stock Exchange of India) under the symbol ZIMLAB.
Zim Laboratories Limited has a trailing twelve-month P/E (price-to-earnings) ratio of 365.0.
Zim Laboratories Limited has a dividend yield of 0.0%.
Zim Laboratories Limited's 52-week high is ₹160.0 and its 52-week low is ₹59.3.
Zim Laboratories Limited has a market capitalisation of ₹756 crore.
Zim Laboratories Limited has a TopFund Quality Score of 45/100 (Weak), a composite of profitability, balance-sheet health, growth and valuation. This is an analytical score based on public data, not personalized investment advice — see the full breakdown below before deciding.
Community Sentiment
What are other investors saying about Zim Laboratories Limited?
No votes yet — be the first to share your view.
Sign in to voteDiscussion
User-generated content — not investment advice, and not verified or endorsed by TopFund.
Sign in to join the discussionNo comments yet — start the discussion.